Plasmatec is a diagnostics business specializing in the manufacture, sale and distribution of a comprehensive range of in vitro diagnostic tests.

Plasmatec Laboratory Products was established in 1990 with the success of the company being built on the quality of the products and the professionalism of the staff. This success was recognised in 2009 when the company was acquired by the Lab21 Group. Lab21 Diagnostic Products division supplies diagnostic kits and reagents that are distributed into over 115 countries globally, focusing on infectious diseases for blood donor screening and routine clinical markets.

Formed through the acquisition of Newmarket, Biotec and Plasmatec laboratories, the company is the leading provider of syphilis tests to national blood supply services throughout Europe and is also a major provider of malaria tests, enabling blood services to maintain high donor numbers. The growing portfolio includes both finished kits and bulk reagents, with two recently launched CMV Kits maintaining the market leading position. The group has continued to grow with the additions of Microgen Bioproducts and Myconostica during 2011.

During 2010, Lab21 expanded the availability of its market leading blood bank screening range of diagnostic assays, by securing a 510(k) clearance in the US for the Syphilis TPHA PK Assay. This is the first of a number of FDA approvals that will be sought as the division looks to expand its distribution presence in the world’s largest diagnostic market.

Lab21 has a professional approach combined with detailed product and market knowledge in all its business areas. This has enabled the company to become a trusted supplier to customers, large and small, throughout the world with customers including a number of aid agencies and various NGO's.

Plasmatec continues to operate from its purpose built facilities based in Bridport, Dorset, UK and operates a Quality management System which is certified to BS EN ISO 9001:2000

Link to Plasmatec